版本:
中国

U.S. FDA approves Novartis' leukemia treatment

April 28 The U.S. Food and Drug Administration on Friday approved Novartis AG's Rydapt as an initial treatment for acute myeloid leukemia (AML).

AML is a rapidly progressing cancer, which forms in the bone marrow and results in an increased number of white blood cells in the bloodstream.

Rydapt has secured approval for adults with newly diagnosed AML that have a specific genetic mutation called FLT3, in combination with chemotherapy, the FDA said. (Reporting by Natalie Grover in Bengaluru)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐